EPZM Stock Price - Epizyme Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.

May. 9, 2018 at 11:20 a.m. ET
on Zacks.com

Cowen & Co. Maintains Their Buy Rating on Epizyme

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Epizyme (NASDAQ: EPZM) today. ...[...]

May. 8, 2018 at 6:08 p.m. ET
on SmarterAnalyst

Oppenheimer Reaffirms Their Buy Rating on Epizyme

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on ...[...]

May. 8, 2018 at 12:11 p.m. ET
on SmarterAnalyst

Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss

Epizyme posted narrower-than-expected loss in the first quarter of 2018. However, the company reported no revenues during the period.

May. 8, 2018 at 8:02 a.m. ET
on Zacks.com

10-Q: EPIZYME, INC.

May. 8, 2018 at 7:19 a.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Stock Performance Review on Exelixis and Three Other Biotech Stocks

Jun. 21, 2018 at 7:27 a.m. ET
on ACCESSWIRE

Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec -- Future Expectations, Projections Moving into 2018

Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec -- Future Expectations, Projections Moving into 2018

Jun. 6, 2018 at 7:55 a.m. ET
on GlobeNewswire

Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data

Jun. 1, 2018 at 7:30 a.m. ET
on GlobeNewswire

Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress

May. 17, 2018 at 9:14 a.m. ET
on GlobeNewswire

Today's Research Reports on Trending Tickers: Epizyme and Valeant Pharmaceuticals

Apr. 24, 2018 at 8:38 a.m. ET
on ACCESSWIRE

Epizyme Provides Update Regarding Tazemetostat Clinical Program

Apr. 23, 2018 at 4:45 p.m. ET
on GlobeNewswire

Recent Analysis Shows Photronics, Just Energy Group, Baidu, Nomura Holdings Inc ADR, KT, and Epizyme Market Influences -- Renewed Outlook, Key Drivers of Growth

Apr. 11, 2018 at 7:55 a.m. ET
on GlobeNewswire

Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology

Apr. 9, 2018 at 6:46 p.m. ET
on GlobeNewswire

New Research: Key Drivers of Growth for GDS HOLDINGS, Nova Measuring Instruments, Magic Software Enterprises, Epizyme, United Community Financial, and Addus HomeCare -- Factors of Influence, Major Initiatives and Sustained Production

Mar. 16, 2018 at 8:01 a.m. ET
on GlobeNewswire

Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones

Mar. 13, 2018 at 7:36 a.m. ET
on GlobeNewswire

Epizyme, Inc. to Host Earnings Call

Mar. 13, 2018 at 6:39 a.m. ET
on ACCESSWIRE

Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors

Mar. 12, 2018 at 4:31 p.m. ET
on GlobeNewswire

Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference

Mar. 12, 2018 at 7:51 a.m. ET
on GlobeNewswire

Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation at the Cowen 38th Annual Health Care Conference

Feb. 27, 2018 at 6:31 a.m. ET
on GlobeNewswire

Epizyme to Participate in Leerink Partners 7th Annual Global Healthcare Conference

Feb. 7, 2018 at 6:30 a.m. ET
on GlobeNewswire

Chondrosarcoma Market Anticipated to Mark a Memorable Growth of CAGR ~3.1% by 2017-2023

Jan. 10, 2018 at 6:57 a.m. ET
on Financeswire

Pre-Market Technical Scan on Biotech Equities -- BioMarin Pharma, Aptevo Therapeutics, Otonomy, and Epizyme

Dec. 12, 2017 at 7:05 a.m. ET
on PR Newswire - PRF

Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting

Dec. 11, 2017 at 7:32 a.m. ET
on GlobeNewswire

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

Dec. 10, 2017 at 10:01 a.m. ET
on GlobeNewswire

Epizyme to Present at the Jefferies 2017 London Healthcare Conference

Nov. 9, 2017 at 6:30 a.m. ET
on GlobeNewswire

Develops therapeutics for the treatment of patients with genetically defined cancers (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 9 Full Ratings

ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax

Jan. 10, 2018 at 5:39 p.m. ET
on Benzinga.com

Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making

Jan. 10, 2018 at 10:27 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For January 10, 2018

Jan. 10, 2018 at 9:21 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Celgene Corp.	0.11%	$57.57B
Seattle Genetics Inc.	1.22%	$10.5B
GlaxoSmithKline PLC ADR	-0.47%	$100.17B
Novartis AG ADR	-1.10%	$193.37B
Abbott Laboratories	0.02%	$106.93B

Competitor Data Provided By

DJIA F	24,396	110	0.45%
S&P F	2,737.50	10.25	0.38%
NASDAQ F	7,155.00	38.50	0.54%
Gold	1,247.70	6.00	0.48%
Silver	15.98	0.145	0.92%
Crude Oil	74.78	0.84	1.14%

Epizyme Inc.

$ 13.60

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Epizyme stock price target cut to $16 from $24 at Leerink

Epizyme downgraded to market perform from outperform at Leerink

Epizyme stock price target raised to $25 vs. $20 at Wedbush

Epizyme started at overweight with $20 stock price target at Morgan Stanley

Epizyme downgraded to sector perform from outperform at RBC Capital

Epizyme downgraded to neutral from buy at Citigroup

Epizyme stock price target cut to $23 from $30 at Citigroup

Cancer firm Epizyme rallies 35% in IPO debut

Stocks

Columns

Authors

Topics

^$ 13.60